Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Case Series of Potential Wernicke's Encephalopathy in Patients Treated with Fedratinib

Claire N. Harrison, BMBCh, DM, FRCP, FRCPath, Ruben A Mesa, MD, Catriona Jamieson, MD PhD, John Hood, PhD, Julie Bykowski, MD, Giulio Zuccoli, MD, James Brewer, MD,PhD

Blood (2017) 130 (Supplement 1): 4197.

https://doi.org/10.1182/blood.V130.Suppl_1.4197.4197

Published: 2017

Journal Articles

Fedratinib Does Not Inhibit Thiamine Uptake or Induce Experimental Wernicke's Encephalopathy in Nonclinical Studies

John Hood, PhD, Alan Hazell, PhD

Blood (2017) 130 (Supplement 1): 4993.

https://doi.org/10.1182/blood.V130.Suppl_1.4993.4993

Published: 2017

Journal Articles

TG101209, a Selective JAK2 Kinase Inhibitor, Suppresses Endogenous and Cytokine-Supported Colony Formation from Hematopoietic Progenitors Carrying JAK2 V617F or MPL W515K/L Mutations.

Animesh Pardanani, MD, PhD, John Hood, PhD, Terra Lasho, Glenn Noronha, PhD, Christy Finke, Chi Ching Mak, PhD, Ruben Mesa, MD, Hong Zhu, PhD, Richard Soll, PhD, Ayalew Tefferi, MD

Blood (2006) 108 (11): 2680.

https://doi.org/10.1182/blood.V108.11.2680.2680

Published: 2006

Journal Articles

Inhibition of JAK2 V617F-Induced Erythroid Skewing of Hematopoietic Stem Cell Differentiation with a Selective JAK2 Antagonist.

Ifat Geron, MS, Charlene Barroga, PhD, Jason Gotlib, MD MS, Edward Kavalerchik, MD, Annelie Abrahamsson, MS, Daniel Goff, BS, Nicholas Cacalano, PhD, John Hood, PhD, Richard Soll, MD, Glenn Noronha, PhD, Ayalew Tefferi, MD, Irving L. Weissman, MD, Kenneth Kaushansky, MD PhD, Catriona Jamieson, MD, PhD

Blood (2006) 108 (11): 3616.

https://doi.org/10.1182/blood.V108.11.3616.3616

Published: 2006

Journal Articles

JAK2 Inhibitors for the Treatment of Myeloprolifertive Disorders.

John Hood, PhD, Jon Cao, PhD, Ehab Hanna, MS, Dan Lohse, PhD, Chi Ching Mak, PhD, Andrew McPherson, PhD, Glenn Noronha, PhD, Joel Renick, MS, Binqi Zheng, PhD, Hong Zhu, PhD, Richard Soll, PhD

Blood (2006) 108 (11): 3632.

https://doi.org/10.1182/blood.V108.11.3632.3632

Published: 2006

NARROW

Case Series of Potential Wernicke's Encephalopathy in Patients Treated with Fedratinib

Fedratinib Does Not Inhibit Thiamine Uptake or Induce Experimental Wernicke's Encephalopathy in Nonclinical Studies

TG101209, a Selective JAK2 Kinase Inhibitor, Suppresses Endogenous and Cytokine-Supported Colony Formation from Hematopoietic Progenitors Carrying JAK2 V617F or MPL W515K/L Mutations.

Inhibition of JAK2 V617F-Induced Erythroid Skewing of Hematopoietic Stem Cell Differentiation with a Selective JAK2 Antagonist.

JAK2 Inhibitors for the Treatment of Myeloprolifertive Disorders.

Email alerts

ASH Publications

American Society of Hematology

Case Series of Potential Wernicke's Encephalopathy in Patients Treated with Fedratinib

Fedratinib Does Not Inhibit Thiamine Uptake or Induce Experimental Wernicke's Encephalopathy in Nonclinical Studies

TG101209, a Selective JAK2 Kinase Inhibitor, Suppresses Endogenous and Cytokine-Supported Colony Formation from Hematopoietic Progenitors Carrying JAK2 V617F or MPL W515K/L Mutations.

Inhibition of JAK2 V617F-Induced Erythroid Skewing of Hematopoietic Stem Cell Differentiation with a Selective JAK2 Antagonist.

JAK2 Inhibitors for the Treatment of Myeloprolifertive Disorders.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only